637 related articles for article (PubMed ID: 28192720)
1. Dendritic cells in cancer: the role revisited.
Veglia F; Gabrilovich DI
Curr Opin Immunol; 2017 Apr; 45():43-51. PubMed ID: 28192720
[TBL] [Abstract][Full Text] [Related]
2. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
Alissafi T; Hatzioannou A; Mintzas K; Barouni RM; Banos A; Sormendi S; Polyzos A; Xilouri M; Wielockx B; Gogas H; Verginis P
J Clin Invest; 2018 Aug; 128(9):3840-3852. PubMed ID: 29920188
[TBL] [Abstract][Full Text] [Related]
3. Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy.
van Gulijk M; Dammeijer F; Aerts JGJV; Vroman H
Front Immunol; 2018; 9():2759. PubMed ID: 30568653
[TBL] [Abstract][Full Text] [Related]
4. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
5. Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer.
Ugolini A; Tyurin VA; Tyurina YY; Tcyganov EN; Donthireddy L; Kagan VE; Gabrilovich DI; Veglia F
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32584791
[TBL] [Abstract][Full Text] [Related]
6. The dendritic cell tool for oral cancer treatment.
Anne Gowda VM; Smitha T
J Oral Maxillofac Pathol; 2019; 23(3):326-329. PubMed ID: 31942108
[TBL] [Abstract][Full Text] [Related]
7. Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy.
Tuettenberg A; Steinbrink K; Schuppan D
Nanomedicine (Lond); 2016 Oct; 11(20):2735-2751. PubMed ID: 27658725
[TBL] [Abstract][Full Text] [Related]
8. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
Front Immunol; 2018; 9():1288. PubMed ID: 29915603
[TBL] [Abstract][Full Text] [Related]
9. The role of dendritic cells in cancer.
Lee YS; Radford KJ
Int Rev Cell Mol Biol; 2019; 348():123-178. PubMed ID: 31810552
[TBL] [Abstract][Full Text] [Related]
10. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells.
Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA
Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy.
Chesney JA; Mitchell RA; Yaddanapudi K
J Leukoc Biol; 2017 Sep; 102(3):727-740. PubMed ID: 28546500
[TBL] [Abstract][Full Text] [Related]
12. The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment.
Agresta L; Hoebe KHN; Janssen EM
Front Immunol; 2018; 9():2809. PubMed ID: 30546369
[TBL] [Abstract][Full Text] [Related]
13. Suppression of T cells by myeloid-derived suppressor cells in cancer.
Chen J; Ye Y; Liu P; Yu W; Wei F; Li H; Yu J
Hum Immunol; 2017 Feb; 78(2):113-119. PubMed ID: 27939507
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-derived suppressor cells and tolerogenic dendritic cells are distinctively induced by PI3K and Wnt signaling pathways.
van Wigcheren GF; Cuenca-Escalona J; Stelloo S; Brake J; Peeters E; Horrevorts SK; Frölich S; Ramos-Tomillero I; Wesseling-Rozendaal Y; van Herpen CML; van de Stolpe A; Vermeulen M; de Vries IJM; Figdor CG; Flórez-Grau G
J Biol Chem; 2023 Nov; 299(11):105276. PubMed ID: 37739035
[TBL] [Abstract][Full Text] [Related]
15. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
Front Immunol; 2018; 9():2250. PubMed ID: 30349530
[TBL] [Abstract][Full Text] [Related]
16. Tumoricidal activity of human dendritic cells.
Tel J; Anguille S; Waterborg CE; Smits EL; Figdor CG; de Vries IJ
Trends Immunol; 2014 Jan; 35(1):38-46. PubMed ID: 24262387
[TBL] [Abstract][Full Text] [Related]
17. β-glucan restores tumor-educated dendritic cell maturation to enhance antitumor immune responses.
Ning Y; Xu D; Zhang X; Bai Y; Ding J; Feng T; Wang S; Xu N; Qian K; Wang Y; Qi C
Int J Cancer; 2016 Jun; 138(11):2713-23. PubMed ID: 26773960
[TBL] [Abstract][Full Text] [Related]
18. The immunobiology of myeloid-derived suppressor cells in cancer.
Motallebnezhad M; Jadidi-Niaragh F; Qamsari ES; Bagheri S; Gharibi T; Yousefi M
Tumour Biol; 2016 Feb; 37(2):1387-406. PubMed ID: 26611648
[TBL] [Abstract][Full Text] [Related]
19. Targeting Myeloid-Derived Suppressor Cells in Cancer.
Anani W; Shurin MR
Adv Exp Med Biol; 2017; 1036():105-128. PubMed ID: 29275468
[TBL] [Abstract][Full Text] [Related]
20. Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs.
Truxova I; Pokorna K; Kloudova K; Partlova S; Spisek R; Fucikova J
Immunol Lett; 2014 Jul; 160(1):39-49. PubMed ID: 24726860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
